Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine for T-cell lymphoma
ACTRN12618000028202Phase 2Completed
- Sponsor
- Monash Health
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of guadecitabine in T-cell lymphoma and mature T-cell malignancies, sponsored by Monash Health. Primary endpoints: Safety and tolerability of guadecitabine administration and Overall response rate. Started May 2018; status: completed.
02
Drugs
guadecitabine
03
Conditions
T-cell lymphomamature T-cell malignancies
Beyond the preview
Go deeper on ACTRN12618000028202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000028202.